

Special Issue

Advances in Plasmid DNA and mRNA as Vaccine Technologies

Message from the Guest Editors

Our Special Issue focuses on "Advances in Plasmid DNA and mRNA as Vaccine Technologies." This Special Issue will cover all of the topics relevant to plasmid DNA and mRNA vaccine design and development for infectious diseases. While both have been under development since the 1990s, in recent years, mRNA has generated significant excitement despite the licensure of several veterinary DNA vaccines. DNA and RNA vaccines are faster and cheaper to produce in large quantities than conventional vaccines. On the other hand, conventional vaccines often use "weakened" or "killed" versions of a virus. This means that laboratories have to produce huge amounts of the virus. They often also include a protein, which is needed to spark a human immune response. However, producing a virus and a viral protein can be time-intensive and expensive. Therefore, this Special Issue will serve as an ideal forum in which scientists can share their latest research findings related to mRNA and plasmid DNA vaccines related to all kinds of diseases. We are looking forward to your interesting manuscript.

Guest Editors

Prof. Dr. Alan Cross

Center for Vaccine Development and Global Health, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Dr. Shumaila Hanif

Basic Sciences, Kentucky College of Osteopathic Medicine (KYCOM) and Kentucky College of Optometry (KYCO), University of Pikeville, Pikeville, KY, USA

Deadline for manuscript submissions

closed (31 May 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/71958

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).